全文获取类型
收费全文 | 1690篇 |
免费 | 100篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 71篇 |
妇产科学 | 12篇 |
基础医学 | 259篇 |
口腔科学 | 31篇 |
临床医学 | 76篇 |
内科学 | 281篇 |
皮肤病学 | 126篇 |
神经病学 | 112篇 |
特种医学 | 223篇 |
外科学 | 202篇 |
综合类 | 14篇 |
一般理论 | 2篇 |
预防医学 | 59篇 |
眼科学 | 7篇 |
药学 | 99篇 |
中国医学 | 5篇 |
肿瘤学 | 212篇 |
出版年
2022年 | 22篇 |
2021年 | 24篇 |
2020年 | 24篇 |
2019年 | 19篇 |
2018年 | 38篇 |
2017年 | 18篇 |
2016年 | 31篇 |
2015年 | 35篇 |
2014年 | 36篇 |
2013年 | 61篇 |
2012年 | 70篇 |
2011年 | 69篇 |
2010年 | 51篇 |
2009年 | 47篇 |
2008年 | 66篇 |
2007年 | 77篇 |
2006年 | 77篇 |
2005年 | 66篇 |
2004年 | 56篇 |
2003年 | 42篇 |
2002年 | 53篇 |
2001年 | 49篇 |
2000年 | 33篇 |
1999年 | 42篇 |
1998年 | 44篇 |
1997年 | 36篇 |
1996年 | 43篇 |
1995年 | 39篇 |
1994年 | 25篇 |
1993年 | 29篇 |
1992年 | 24篇 |
1991年 | 28篇 |
1990年 | 32篇 |
1989年 | 44篇 |
1988年 | 38篇 |
1987年 | 31篇 |
1986年 | 34篇 |
1985年 | 32篇 |
1984年 | 20篇 |
1983年 | 21篇 |
1982年 | 28篇 |
1981年 | 16篇 |
1980年 | 18篇 |
1978年 | 10篇 |
1977年 | 17篇 |
1976年 | 15篇 |
1975年 | 9篇 |
1974年 | 5篇 |
1973年 | 7篇 |
1966年 | 4篇 |
排序方式: 共有1803条查询结果,搜索用时 15 毫秒
1.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献2.
3.
4.
5.
B Gerdts AFPM Vloemans RW Kreis 《Journal of the European Academy of Dermatology and Venereology》2007,21(6):781-788
BACKGROUND: Toxic epidermal necrolysis (TEN) is a severe and potentially fatal drug reaction characterized by an extensive skin rash with blisters and exfoliation, frequently accompanied by mucositis. The wounds caused by TEN are similar to second-degree burns and severe cases may involve large areas of skin loss. OBJECTIVES: Analysis of our results in patients with TEN and evaluation of the variety of therapeutic interventions that has been studied and suggested in TEN. PATIENTS/METHODS: Retrospective analysis of 19 consecutive patients with TEN treated in our burns centre between 1989 and 2004. RESULTS: Immediate withdrawal of any potentially fatal drug, maximum supportive care, and a restricted and tailored antibiotic, medical and surgical treatment regimen confined mortality to 21%, whereas prognosis scores like APACHE II and SCORTEN predicted mortality of 22 and 30%, respectively. A positive contribution of selective digestive decontamination is suggested but has yet to be established. CONCLUSIONS: Because of a potentially fatal outcome, fast referral of a patient suspected of TEN to a specialized centre (mostly a burns unit or specialized dermatology centre) for expert wound management and tailored comprehensive care is strongly advised and contributes to survival. 相似文献
6.
1背景 育龄妇女常见慢性下腹痛,可造成身体损害、情绪忧伤及导致巨大的健康服务费用。美国在这方面的花费超过8亿8千万美元(Mathias 1996)。英国全国数据库的一般性诊治资料显示,慢性下腹痛发病率及流行率与偏头痛、背部痛、哮喘发病率相似(Zondervan 1999)。 相似文献
7.
8.
In an open, non-randomized 3-way cross-over study, the bioavailability of 2-oxo-pyrrolidine-1-acetamide (piracetam, Encetrop) from two solid oral formulations and one liquid formulation was tested in 8 healthy male volunteers. The area under the concentration time curve, which is defined to be a measurement for bioequivalence among the three tested galenic formulations correlated very well with the area under the effect intensity-time curve, which was estimated in the same volunteers using electro-physiological methods. The different methods of estimation of bioequivalence show similarity between both solid galenic formulations, while the liquid form exhibits superiority in respect to the oral solid formulations. 相似文献
9.
10.
Jörg Bohmeyer Andreas Heller Christine Hartig Margaretha Westenberger-Treumann Hans Huchzermeyer Heinz-Günter Otte Rudolf Stadler 《Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete》1996,47(2):106-108
Zusammenfassung
Trotz der H?ufigkeit der Erkrankung liegen nur wenige gesicherte Erkenntnisse über die ?tiologie der chronischen Urtikaria
vor. Bei 10 Patienten, bei denen keine anderweitige Ursache für die Erkrankung ermittelt werden konnte, führten wir eine Gastroskopie
durch. Bei 8 der 10 Patienten konnte eine Besiedlung der Magenschleimhaut mit Helicobacter pylori gesichert werden. Die Urtikaria
heilte innerhalb weniger Tage bei allen Patienten ab, nachdem wir eine Therapie mit Amoxicillin und Omeprazol einleiteten.
Eingegangen am 6. Februar 1995 Angenommen am 12. Mai 1995 相似文献